Dr Rachel Giles guides us through 6 abstracts from the 56th EASD Annual Meeting:
- Ertugliflozin offers some kidney protection - Cherney et al.
- Empagliflozin significantly reduces CV and renal risk - Packer et al.
- Once daily oral treatment with glucokinase activator TTP399 reduced HbA1c in patients with type 1 diabetes - Valcarce et al.
- Diabetes still goes unnoticed, resulting in delayed diagnosis - Young et al.
- Once-weekly insulin is a promising treatment option - Rosenstock et al.
- Intermittent fasting: consuming fewer calories but in a different way - Varady et al.
Posted on
Table of Contents: EASD 2020
Featured articles
EASD Round-Up Articles
Ertugliflozin offers some kidney protection
DAPA-CKD trial shows extensive benefits of dapagliflozin
Empagliflozin significantly reduces CV and renal risk
Poor prognosis for T2D patients on loop diuretics in addition to SGLT2 inhibitor
High risk of vascular dementia in patients with T2D
HbA1c reduction with GLP-1RA leads to lower risk of CV events in cardiovascular outcome trials
Diabetes still goes unnoticed, resulting in delayed diagnosis
Patients with RA have higher risk of developing diabetes
Once-weekly insulin is a promising treatment option
Non-invasive monitoring by measuring glycated albumin in tears
More exercise means less risk of all-cause mortality amongst T2D patients.
Intermittent fasting: consuming fewer calories but in a different way.
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com